Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from WuXi XDC Cayman, Inc. ( (HK:2268) ).
WuXi XDC Cayman Inc. announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in January 2026, using the event to share detailed information on its business operations with investors while simultaneously disclosing the same material to the market. The company reported strong business and financial performance in 2025, highlighting a total of 1,291 projects, including 70 newly signed integrated chemistry, manufacturing and controls projects and 10 new process performance qualification projects, which underscore its growing commercial potential. With more than 600 customers served globally, over 120 global IND submissions completed, and 70 projects progressing from discovery to iCMC stage via its ADC CRDMO platform, WuXi XDC is reinforcing its position as a key player in the ADC outsourcing space. The group is also expanding its operational footprint in China and Singapore, with further domestic and overseas sites planned, and it maintains confidence in sustaining its growth momentum into 2026, signaling continued scaling and capacity expansion for stakeholders.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$90.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
More about WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc. is a contract research, development and manufacturing organization (CRDMO) specializing in antibody-drug conjugates (ADCs), providing integrated chemistry, manufacturing and controls (iCMC) and related services to biopharmaceutical customers worldwide. The group focuses on supporting global drug development from discovery through to commercial stages, with a growing footprint in China, Singapore and other planned domestic and overseas sites to serve more than 600 customers and advance hundreds of projects, including over 120 global IND submissions.
Average Trading Volume: 4,547,644
Technical Sentiment Signal: Buy
Current Market Cap: HK$89.5B
See more insights into 2268 stock on TipRanks’ Stock Analysis page.